About 7 results found for searched term "Bcl-2" (0.053 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M13532 | S55746 | Bcl-2 |
| BCL201 | ||
| S55746 (BCL201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BCL201) has antitumor activity with low toxicity. | ||
| M13533 | S55746 hydrochloride | Bcl-2 |
| BCL201 hydrochloride | ||
| S55746 hydrochloride (BCL201 hydrochloride) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 hydrochloride (BCL201 hydrochloride) has antitumor activity with low toxicity. | ||
| M22479 | Lisaftoclax | Bcl-2 |
| APG-2575; Bcl-2/Bcl-xl inhibitor 1 | ||
| Lisaftoclax (APG-2575) is a dual Bcl-2 and Bcl-xl inhibitor with anti-tumor activity, exhibits IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively. | ||
| M28068 | A-1211212 | Bcl-2 |
| BCL2-IN-1 | ||
| A-1211212 (BCL2-IN-1) is a potent Bcl-2 inhibitor. BCL2-IN-1 binds Bcl-2 with a Ki of <0.01 nM. | ||
| M29577 | PROTAC Bcl2 degrader-1 | PROTAC |
| PROTAC Bcl2 degrader-1 (Compound C5) is a PROTAC based on Cereblon ligand, which potently and selectively induces the degradation of Bcl-2 (IC50, 4.94 μM; DC50, 3.0 μM) and Mcl-1 (IC50, 11.81 μM) by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitor Nap-1. | ||
| M41317 | Bcl-2-IN-11 | Bcl-2 |
| Bcl-2-IN-11 is a potent and selective Bcl-2 activity inhibitor, with an IC50 of 0.9 nM. | ||
| M41436 | CDK2/Bcl2-IN-1 | CDK |
| CDK2/Bcl2-IN-1 with promising cytotoxicity against cancer cells. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
